Health
DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19 – News-Medical.Net
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3…
RedHill Biopharma Ltd. (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.
Opaganib is a novel, orally-administered sphingosine…
-
Noosa News23 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News22 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Business8 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General18 hours ago‘Potential’ hacker contacts Qantas over data breach